Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Graft Vs Host Disease: early-phase trial registry
12 of 37 indexed Graft Vs Host Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #406 of 28,707 conditions by registered trial count.
37 US clinical trials · 12 currently recruiting · #406 of 28,707 conditions by registered trial count
Graft Vs Host Disease: 37 US clinical trials tracked, 12 recruiting.
Graft Vs Host Disease is the subject of 37 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 5 of these trials.
Enrollment posture brief
Registry condition graft-vs-host-disease
OPEN 12 | RECR 32% | LATE 1 | EARLY 21 | RANK #406 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Tobacco Use Cessation (32% recruiting · 37 trials)
Graft Vs Host Disease lists 12 open slots (32% of 37 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Graft Vs Host Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Graft Vs Host Disease is recruiting below its size-band peers.
12 of 37 indexed trials (32.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Graft Vs Host Disease trials is spread across many organizations.
Dana-Farber Cancer Institute accounts for 5 of 37 trials (13.5%). 24 distinct sponsors appear on at least one study for this condition label.
-
Most Graft Vs Host Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 46 among the 37 trials that report a genuine target (sentinel values excluded). 25 of those (67.6%) plan for fewer than 100 participants.
-
Graft Vs Host Disease research is mostly interventional.
28 interventional and 9 observational studies make up this index (75.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
37 total, page 1 of 1
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
National Heart, Lung, and Blood Institute (NHLBI)
NCT00106925
Pediatric cGVHD Symptom Scale
National Cancer Institute (NCI)
NCT04044365
Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
Children's Hospital Medical Center, Cincinnati
NCT06450925
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
Boston Children's Hospital
NCT04380740
A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant
Christopher Dvorak
NCT04337515
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
National Cancer Institute (NCI)
NCT05531786
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT07006506
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT06008808
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
Case Comprehensive Cancer Center
NCT06649201
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
Dana-Farber Cancer Institute
NCT05236062
IS-free Treg HaploHCT
Dana-Farber Cancer Institute
NCT04678401
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Northwell Health
NCT06681922
Chronic GVHD Response Measures Validation
Fred Hutchinson Cancer Center
NCT01902576
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland
NCT03229200
Multidisciplinary Intervention In Chronic GVHD
Massachusetts General Hospital
NCT04479995
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
National Heart, Lung, and Blood Institute (NHLBI)
NCT02105766
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases
University of Utah
NCT04922736
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
NYU Langone Health
NCT05621759
Horizons Chronic Graft-Versus-Host-Disease Study
University of Miami
NCT06160986
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Fred Hutchinson Cancer Center
NCT01206309
Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
Dana-Farber Cancer Institute
NCT02867384
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
National Heart, Lung, and Blood Institute (NHLBI)
NCT00224874
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers
National Heart, Lung, and Blood Institute (NHLBI)
NCT00001873
Evaluation of the Impact of Reduced Immunosuppression
Methodist Health System
NCT05238155
Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant
Vanderbilt University
NCT00179049
Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
H. Lee Moffitt Cancer Center and Research Institute
NCT01713400
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
Regimmune Corporation
NCT04014790
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
H. Lee Moffitt Cancer Center and Research Institute
NCT02891603
A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease
University of Michigan Rogel Cancer Center
NCT01700036
Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT
University of Florida
NCT02398708
Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease
Facet Biotech
NCT00032292
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
Mesoblast
NCT00136903
Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease
Dana-Farber Cancer Institute
NCT00136396
Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT04131738
Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
University of Michigan Rogel Cancer Center
NCT01790568
Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
Dana-Farber Cancer Institute
NCT01221766
Topical Vitamin D in Acute Graft Versus Host Disease of the Skin
Children's Hospital Medical Center, Cincinnati
NCT03093805
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 13 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Graft Vs Host Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Graft Vs Host Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Graft Vs Host Disease page
37 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Graft Vs Host Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most Graft Vs Host Disease trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Graft Vs Host Disease condition card totals 37 registered trials; most-linked intervention Tacrolimus; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.